Insurance-mandated Weight Management Programs Prior to Bariatric Surgery Offer No Clinical Benefit
Insurance companies believe the required presurgical programs reduce complications and improve outcomes but a new study strongly suggests the opposite.
How to Identify & Evaluate Chronic Kidney Disease Using eGFR and UACR: In brief
Primary care clinicians are critical to screening and caring for CKD. This "In brief" slide show reviews the 2 key lab tests used to diagnose the disease.
Antiobesity Medications May Support Long-term 10% Weight Loss, Suggests New Study
ENDO 2022: Findings from the long-term, real-world study of meds for maintenance of meaningful weight loss support wider uptake of the agents, authors say.
Older Adults Today More Likely to Have Multiple Chronic Conditions than Prior Generations
Baby Boomers had more chronic health conditions and more conditions at younger ages than older adults born at the end of the Great Depression.
Prediabetes Independently Associated with MI, PCI, CABG: A "Wake-up Call," Study Authors Say
ENDO 2022: The large US analysis found persons with prediabetes had increased odds for heart attack of 25%, for PCI of 45%, and had nearly double the risk of having CABG.
Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c
ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.
Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM
ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.
Poorly Controlled T2D Improves with Initiation of rtCGM in Primary Care
ADA 2022: Primary care patients with T2D and HbA1c >7.5% achieved as much as a 1.5% drop in HbA1c after initiating real time continuous glucose monitoring.
Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight, Obesity
ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.
Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c
ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.
Finerenone Cardiorenal Effects in T2D Consistent Across Baseline HbA1c, Disease Duration
ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.
Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.
Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function
ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
DiabetesWise Pro lets clinicians compare diabetes devices for a specific patient and provides the steps for ordering the device based on insurance type.
CGM News: FreeStyle Libre 3 Cleared by FDA for Persons Aged 4 Years and Older with Diabetes
The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.
Gen Z Youth Want Their Physicians to Ask Them about Social Determinants of Health
A new survey of youth aged 14 to 24 years provides significant support for integrating questions about social needs into routine clinical care.
Time to Benefit Following Intensive BP Reduction in Adults Aged 60 Years and Older
The first study of its kind found that intensive blood pressure control may be most beneficial in older adults with life expectancy greater than 3 years vs less than 1 year.
Treatment Gap: In Patients with ASCVD, Low Use of Statins, High-intensity Statins Persists
One-half of more than 600 000 patients with ASCVD were not prescribed statins at all and only 22.5% were taking a high intensity statin, according to a recent study.
Pfizer Wins Fast Track Designation for Potential NASH Drug Combination
Early phase 2a study results of a combination of the 2 agents previously evaluated as NASH monotherapies led to the FDA award for Pfizer.
Risk for HF Hospitalization in Type 2 Diabetes Lower with First-line SGLT-2 Inhibitor vs Metformin
Initiating T2D treatment with an SGLT2 inhibitor reduced risk for heart failure hospitalization compared to metformin in a new study; cardiovascular outcomes were similar.
National Kidney Foundation Urges USPSTF to Prioritize Screening Recommendation for CKD
The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."
Metformin, Lifestyle in Prediabetes May Reduce Risk of T2D but Not Major CV Events
Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.
FDA Grants EUA for At-home Triple Test: COVID-19, Influenza, RSV
The Labcorp home test, available without a prescription, is delivered overnight and includes a return envelope. Results are available in 1-2 days.
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.
CDC Greenlights COVID-19 Booster for Children Aged 5 to 11 Years
The CDC is encouraging parents of children in this age group to first finish a primary vaccination series, saying only 28% now are in that category.
Early, Consistent Glucose Control May Be Key to CVD Risk Reduction in Type 2 Diabetes: A Primary Care Analysis
In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.
SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.